Roche (ROG: SIX) has entered into a multiyear collaboration with PureTech Health (LSE: PRTC) to advance the latter’s milk-derived exosome platform technology for the oral administration of the Swiss pharma giant’s antisense oligonucleotide platform.
PureTech, a UK-based clinical-stage biopharmaceutical company developing novel medicines focused on the Brain-Immune-Gut (BIG) Axis, saw its shares gain as much as 9.15% to 155.00 pence on the news this morning.
The companies are aiming to take advantage of the way milk is designed by nature to transport essential molecules between mother and offspring. This makes it a potentially effective vehicle for oral medicines which would otherwise break down in the stomach.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze